Changes in Hong Kong stocks | Baixinan-B (02185) is now up more than 4% IBERIS RDN system recently registered in New Zealand

The Zhitong Finance App learned that Baixinan-B (02185) is now up more than 4%. As of press release, it has risen 4.13% to HK$6.56, with a turnover of HK$1.182,400.

According to the news, Baixinan previously announced that the Iberis multipole renal artery radiofrequency ablation catheter system developed by its subsidiary Shanghai Antong Medical Technology Co., Ltd. has completed registration in New Zealand. The Iberis RDN system is the only renal nerve blocking product approved in the world using the transradial artery method and the transfemoral artery approach method.

Huafu Securities previously released a research report stating that the Baixinan Iberis RDN system is the only one approved for listing in the world that can have both transradial artery (TRA) and transfemoral artery dual access RDN, with a remarkable first-mover advantage. China has already reached major strategic cooperation with Yuanda Health and many overseas countries and regions; Germany and France have included Iberis RDN in health insurance, and is currently the starting point for the commercialization of Baixinan.